China’s Akesobio sets ball rolling for HK listing

By Jonathan Breen
04 Dec 2019

Akesobio, a Chinese biopharmaceuticals company, filed a draft prospectus for an IPO with Hong Kong’s stock exchange on Tuesday.

The firm submitted the documents through joint sponsors, bulge bracket banks JP Morgan and Morgan Stanley. It is tapping the capital markets to raise funds for research and development and the commercialisation of its products, as well as to develop manufacturing and R&D facilities in Guangzhou and Zhongshan ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial